- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04360525
Different Clinicopathological Features of Non-Elderly Sigmoid Volvulus Patients
April 21, 2020 updated by: Ufuk Uylas, Dr. Ersin Arslan Education and Training Hospital
Sigmoid volvulus is frequently seen in male patients over 60 years old.
In the sigmoid volvulus <60 age groups, the male/female ratio is close to each other.
If sigmoid volvulus develops in <60 age groups, it is more likely to be another underlying organic pathology.
Study Overview
Detailed Description
Sigmoid volvulus is frequently seen in male patients over 60 years old.
Here, the investigators aimed to investigate the causes of sigmoid volvulus developing in patients under 60 years of age.
Patients diagnosed with sigmoid volvulus between 2009 and 2018 were retrospectively screened.
The patients were divided into two as under 60 years old and above.
The co-morbidity, mortality, morbidity, complications, age and gender data of the patients were analyzed.
In the sigmoid volvulus <60 age groups, the male/female ratio is close to each other.
If sigmoid volvulus develops in <60 age groups, it is more likely to be another underlying organic pathology.
Study Type
Observational
Enrollment (Actual)
134
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Gaziantep, Turkey
- Dr. Ersin Arslan Training and Resource Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who were treated for the sigmoid volvulus between 2009 and 2018 at Inonu University General Surgery Clinic.
Description
Inclusion Criteria:
- Sigmoid volvulus patients under the age of 60
- Sigmoid volvulus patients at the age of ≥60
Exclusion Criteria:
- Lack of data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Elderly patients
Elderly patients (60≤ age) with sigmoid volvulus
|
Causes of sigmoid volvulus
|
|
Young patients
Young patients (<60 age) with sigmoid volvulus
|
Causes of sigmoid volvulus
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality
Time Frame: up to three months
|
Elderly and young patients mortality
|
up to three months
|
|
Morbidity
Time Frame: up to three months
|
Elderly and young patients morbidity
|
up to three months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 1, 2020
Primary Completion (ACTUAL)
April 1, 2020
Study Completion (ACTUAL)
April 18, 2020
Study Registration Dates
First Submitted
April 18, 2020
First Submitted That Met QC Criteria
April 21, 2020
First Posted (ACTUAL)
April 24, 2020
Study Record Updates
Last Update Posted (ACTUAL)
April 24, 2020
Last Update Submitted That Met QC Criteria
April 21, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18042020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pathology
-
University of RochesterAmerican Orthopaedic Foot and Ankle SocietyCompleted
-
Assistance Publique Hopitaux De MarseilleUnknown
-
Consorci Sanitari de TerrassaUnknownGynecological PathologySpain
-
University Hospital, Strasbourg, FranceUnknownRespiratory Pathology | Obstructive SyndromeFrance
-
Dr. Ersin Arslan Education and Training HospitalCompleted
-
University Hospital, MotolCompletedECMO Primary Hemostasis PathologyCzechia
-
Arthrex, Inc.TerminatedDegenerative and Traumatic Pathology of the Knee | Degenerative and Traumatic Pathology of the Shoulder and Elbow | Degenerative and Traumatic Pathology of the Foot and Ankle | Degenerative and Traumatic Pathology of the Hand and Wrist | Degenerative and Traumatic Pathology of the HipUnited States, United Kingdom, South Africa, Canada, Puerto Rico
-
Rigshospitalet, DenmarkCompleted
-
Hamamatsu Photonics K.K.Completed
-
Uelk, J. Daniel, D.O.Unknown
Clinical Trials on Reasons
-
University Hospital, BrestCompletedElectromagnetic FieldFrance
-
Amsterdam UMC, location VUmcCompleted
-
HaEmek Medical Center, IsraelCompletedInfection Rate After Fingertip AmputationIsrael
-
Recep Tayyip Erdogan University Training and Research...CompletedBone Diseases | Cone-beam Computed Tomography | Florid Cemento-osseous DysplasiaTurkey
-
University Hospital, Basel, SwitzerlandCompleted
-
Eli Lilly and CompanyCompleted
-
Ironwood Pharmaceuticals, Inc.Allergan Sales, LLCCompletedIrritable Bowel Syndrome Characterized by ConstipationUnited States
-
Ironwood Pharmaceuticals, Inc.Forest LaboratoriesCompletedIrritable Bowel Syndrome With ConstipationUnited States
-
Region SkaneSwedish Lung Cancer Study GroupRecruitingNon-Small Cell Lung CancerSweden